Overcoming drug resistance in skin cancer
- Researcher: Dr Bin Zheng
- Institution: Massachusetts General Hospital, Boston, USA
- Award Amount: £215,731 for 3 years from 1st January 2019
- Cancer Type: melanoma, Skin Cancer
Around 60% of all melanomas carry a genetic mutation to a gene called “B-Raf” and drugs that target this mutation show a lot of success in the clinic. However, many patients go on to develop resistance to this class of drugs known as BRAF inhibitors. Dr Bin Zheng at Massachusetts General Hospital, Boston, USA, is working out how this resistance occurs to find ways to overcome it.
Dr Zheng and his team are looking at how melanoma cells alter the way they obtain and utilise energy from the sugar glucose when they become resistant to BRAF inhibitors. Through their studies, they hope to uncover new therapeutics strategies that could be used to develop drugs targeting resistant cancer cells.
The Research That Is Happening Right Now
Explore current projects to see how far-reaching our research is from a global perspective.
See the difference our research projects make.